They may suggest a treatment to manage your symptoms and can determine whether you should keep taking Ebglyss or Dupixent. If you have symptoms of a severe allergic reaction, such as swelling or ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Monoclonal antibodies (mAbs) are a relatively new treatment for asthma ... autoinjector pen severe eosinophilic asthma 12 years and older Dupilumab (Dupixent) Interleukin-4Rα prefilled syringe ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

The final appraisal document for Dupixent (dupilumab ... in five people with suspected severe asthma are not being referred to specialists for the treatments that could transform, and even ...

and uncertainty in the population eligible for this kind of treatment. Dupixent, an interleukin-4 and 13 inhibitor, was approved in Europe in asthma in May last year, following a previous approval ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Medically reviewed by Casey Gallagher, MD Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with ...

Sanofi (NASDAQ:SNY) announced today that Japan’s Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Dupixent (dupilumab) as a treatment for adults ...